Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

988 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Molecular tumor board: the University of California-San Diego Moores Cancer Center experience.
Schwaederle M, Parker BA, Schwab RB, Fanta PT, Boles SG, Daniels GA, Bazhenova LA, Subramanian R, Coutinho AC, Ojeda-Fournier H, Datnow B, Webster NJ, Lippman SM, Kurzrock R. Schwaederle M, et al. Among authors: kurzrock r. Oncologist. 2014 Jun;19(6):631-6. doi: 10.1634/theoncologist.2013-0405. Epub 2014 May 5. Oncologist. 2014. PMID: 24797821 Free PMC article.
Unique molecular signatures as a hallmark of patients with metastatic breast cancer: implications for current treatment paradigms.
Wheler JJ, Parker BA, Lee JJ, Atkins JT, Janku F, Tsimberidou AM, Zinner R, Subbiah V, Fu S, Schwab R, Moulder S, Valero V, Schwaederle M, Yelensky R, Miller VA, Stephens MP, Meric-Bernstam F, Kurzrock R. Wheler JJ, et al. Among authors: kurzrock r. Oncotarget. 2014 May 15;5(9):2349-54. doi: 10.18632/oncotarget.1946. Oncotarget. 2014. PMID: 24811890 Free PMC article.
Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analyses.
Tsimberidou AM, Wen S, Hong DS, Wheler JJ, Falchook GS, Fu S, Piha-Paul S, Naing A, Janku F, Aldape K, Ye Y, Kurzrock R, Berry D. Tsimberidou AM, et al. Among authors: kurzrock r. Clin Cancer Res. 2014 Sep 15;20(18):4827-36. doi: 10.1158/1078-0432.CCR-14-0603. Epub 2014 Jul 1. Clin Cancer Res. 2014. PMID: 24987059 Free PMC article.
Triple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: improved outcomes with combination chemotherapy and targeted agents.
Ganesan P, Moulder S, Lee JJ, Janku F, Valero V, Zinner RG, Naing A, Fu S, Tsimberidou AM, Hong D, Stephen B, Stephens P, Yelensky R, Meric-Bernstam F, Kurzrock R, Wheler JJ. Ganesan P, et al. Among authors: kurzrock r. Mol Cancer Ther. 2014 Dec;13(12):3175-84. doi: 10.1158/1535-7163.MCT-14-0358. Epub 2014 Sep 24. Mol Cancer Ther. 2014. PMID: 25253784 Free PMC article.
Synergy between VEGF/VEGFR inhibitors and chemotherapy agents in the phase I clinic.
Tang C, Hess K, Jardim DL, Gagliato Dde M, Tsimberidou AM, Falchook G, Fu S, Janku F, Naing A, Piha-Paul S, Subbiah V, Wheler J, Zinner RG, Kurzrock R, Ellis LM, Meric-Berstam F, Hong DS. Tang C, et al. Among authors: kurzrock r. Clin Cancer Res. 2014 Dec 1;20(23):5956-63. doi: 10.1158/1078-0432.CCR-14-1582. Epub 2014 Oct 14. Clin Cancer Res. 2014. PMID: 25316815 Clinical Trial.
Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I Clinic.
Jardim DL, Tang C, Gagliato Dde M, Falchook GS, Hess K, Janku F, Fu S, Wheler JJ, Zinner RG, Naing A, Tsimberidou AM, Holla V, Li MM, Roy-Chowdhuri S, Luthra R, Salgia R, Kurzrock R, Meric-Bernstam F, Hong DS. Jardim DL, et al. Among authors: kurzrock r. Clin Cancer Res. 2014 Dec 15;20(24):6336-45. doi: 10.1158/1078-0432.CCR-14-1293. Epub 2014 Oct 17. Clin Cancer Res. 2014. PMID: 25326232
Cyclin alterations in diverse cancers: Outcome and co-amplification network.
Schwaederlé M, Daniels GA, Piccioni DE, Fanta PT, Schwab RB, Shimabukuro KA, Parker BA, Kurzrock R. Schwaederlé M, et al. Among authors: kurzrock r. Oncotarget. 2015 Feb 20;6(5):3033-42. doi: 10.18632/oncotarget.2848. Oncotarget. 2015. PMID: 25596748 Free PMC article.
988 results